Luminex Announces Development Collaboration and License Agreement with Major Healthcare and Research Organization

Business Wire, Nov 27, 2007

AUSTIN, Texas & ROCHESTER, Minn. -- Luminex Corporation (Nasdaq: LMNX), the world leader in multiplexed solutions, and Mayo Clinic today announced that they have signed a development licensing agreement that enables Mayo to provide genetic and other testing services to patients using Luminex's xMAP[R] technology. The agreement contains collaboration and licensing provisions for the inherited disorder thalassemia and also provides opportunities for additional test content creation.

"The Mayo Clinic has been a leader in the field of diagnostics for many years, paving the way to improve detection, monitoring and treatment of many medical conditions," said Patrick J. Balthrop, president and chief executive officer of Luminex. "We are thrilled to collaborate with Mayo to develop new genetic testing services for thalassemia and look forward to supporting additional ways our xMAP technology can be used to enhance the diagnosis and treatment of patients with other conditions."

Thalassemia, sometimes referred to as Mediterranean anemia, is an inherited blood disorder caused by defects in the genes that make hemoglobin. Those with thalassemia have less hemoglobin and fewer red blood cells than those without the disease, which results in anemia. It is estimated that over two million people in the United States carry the genetic trait for thalassemia.

Mayo Clinic will enhance its current genetic testing services for thalassemia to include a new molecular diagnostic test based on Multiplex Ligation-dependent Probe Amplification (MLPA) and bead-based liquid micro-array technology using xMAP technology from Luminex. The advantages to the patient are as follows:

* more probes coding the region enables improved detection of deletions, even within the promoter region of the genes

* a reduction in turnaround time of test results from 7-10 days to 2-3 days

* an increased number of measurements translates into decreased variability of the test results

* eliminates the need for radio-active elements in the test

In its mildest forms, thalassemia may not require any treatment, but more severe forms of the disease may necessitate regular blood transfusions. As with many genetic disorders, early and accurate detection is essential in effective treatment and management of the disease.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP[R] multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained at www.luminexcorp.com.

About Mayo Clinic

Mayo is a private group practice of medicine dedicated to providing diagnosis and treatment of patient illnesses through a systematic focus on individual patient needs. Mayo provides comprehensive hospital and outpatient services at each of its major locations -- Rochester, MN; Jacksonville, FL; and Scottsdale, AZ. The Department of Laboratory Medicine and Pathology at Mayo Clinic maintains an active diagnostic test development program. Mayo utilizes these proven diagnostic technologies in the care of its patients and offers them to more than 5,000 health care institutions around the world through Mayo Medical Laboratories. Revenue from Mayo Medical Laboratories is used to support medical education and research at Mayo Clinic. Visit www.MayoMedicalLaboratories.com for additional information.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, including Tm Bioscience Corporation, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.